A Bayer heart failure project gets a high-profile unveiling, while Amarin and Esperion get a chance to reinforce their lipid-lowering candidates.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,